Semaglutide vs Tirzepatide

AOD-9604 and Semaglutide are both studied for fat loss, but they exist on completely different tiers of clinical evidence. Semaglutide is FDA-approved with extensive phase III data, while AOD-9604 is a synthetic fragment of growth hormone that failed to achieve regulatory approval for obesity despite early promise.

Semaglutide and Retatrutide represent two different generations of incretin-based weight loss therapies. Semaglutide is a GLP-1 receptor agonist with extensive clinical data and FDA approval, while Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor activation distinguishes Retatrutide from all currently approved therapies and introduces a thermogenic component that may drive greater fat loss -- but it remains in clinical trials.

Tirzepatide and Retatrutide are both multi-receptor agonists developed by Eli Lilly, but they target different numbers of receptors. Tirzepatide is a dual GIP/GLP-1 agonist with FDA approval and robust phase III data, while Retatrutide adds a third target -- the glucagon receptor -- creating the first triple agonist in clinical development for obesity. This comparison examines whether the additional glucagon receptor activation translates to meaningfully better outcomes.

Semaglutide and Tesofensine represent two fundamentally different pharmacological approaches to weight loss. Semaglutide is a GLP-1 receptor agonist that reduces appetite through gut-brain hormonal signaling -- it is FDA-approved and backed by extensive Phase III clinical data. Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, and dopamine) that suppresses appetite through central nervous system stimulation. Tesofensine reached Phase II trials with impressive weight loss results but has not advanced to Phase III approval due to cardiovascular safety concerns. This comparison examines the evidence, safety profiles, and practical considerations for each.